fda statement on compounded semaglutide is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA Ban on Compounded GLP-1

A small activation of the gastric inhibitory polypeptide (GIP) receptor was detected at concentrations above 1 M (Supplementary Fig

This triple action aids in blood sugar regulation, appetite control, and energy expenditure, providing a promising approach to weight loss and metabolic health

While those changes can support weight-management goals, they can also affect how much fluid people naturally consume

Alternative treatment options, dose adjustments, or additional support may be available to address your concerns whilst maintaining diabetes control

A COA should be reviewed for the information it actually documents